Compare TOMZ & BNGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TOMZ | BNGO |
|---|---|---|
| Founded | 1979 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5M | 11.6M |
| IPO Year | 2009 | 2018 |
| Metric | TOMZ | BNGO |
|---|---|---|
| Price | $0.64 | $1.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $3.50 | ★ $6.33 |
| AVG Volume (30 Days) | ★ 216.1K | 98.5K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $7,738,842.00 | ★ $12,000,735.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $68.67 | $24.27 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 5.23 | ★ 26.26 |
| 52 Week Low | $0.54 | $1.06 |
| 52 Week High | $1.20 | $5.50 |
| Indicator | TOMZ | BNGO |
|---|---|---|
| Relative Strength Index (RSI) | 40.89 | 38.12 |
| Support Level | $0.54 | $1.06 |
| Resistance Level | $0.81 | $1.18 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 45.14 | 29.70 |
TOMI Environmental Solutions Inc is a leader in bacteria decontamination and infectious disease control, offering environmentally friendly solutions for indoor air and surface disinfection and decontamination. Its flagship product, SteraMist, uses patented and registered Binary Ionization Technology (BIT) to deliver a low-percentage (7.8%) hydrogen peroxide-based fog or mist to affect all indoor environments and surface areas. Its product portfolio includes The SteraPak, The Surface Unit, The Transport, The NV+, The Environment System, SteraMist Integrated System, BIT Solution, and Custom Engineered System.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.